The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
20-Sep-21
Undisclosed
Target:
Faes Farma, flagship product Bilastine
Acquiror:
Hikma Specialty USA INC
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
14-Jul-21
Undisclosed
Target:
New Day Aluminum LLC
Acquiror:
Concord Resources Ltd.
Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.
30-Jun-21
Pending
Undisclosed
Target:
Deltalab
Acquiror:
SCG Packaging Public Company Limited
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
28-Jun-21
Pending
Undisclosed
Target:
Portfolio of 16 European Consumer Healthcare brands from Sanofi
Acquiror:
STADA Arzneimittel AG
Advising Sanofi, a leading global player in the Consumer Healthcare market, on the divestiture of a portfolio of 16 European Consumer Healthcare brands to STADA, a German pharmaceutical and consumer healthcare company owned by Bain Capital and Cinven
01-Jun-21
Undisclosed
Target:
VEP Healthcare
Acquiror:
U.S. Acute Care Solutions
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
31-Mar-21
Pending
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advising Procaps Group, a leading global pharmaceutical technology and healthcare company based in Colombia, on its merger with Union Acquisition Corp. II (NASDAQ: LATN), a special purpose acquisition company
26-Feb-21
Undisclosed
Target:
MDLIVE
Acquiror:
Cigna
Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio
11-Feb-21
Undisclosed
Target:
Alumisource Corporation
Acquiror:
Sims Limited
Advised Sims Limited, a global leader in metal recycling and electronics recovery, on the acquisition of certain commercial and operating assets of Alumisource Corporation
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
04-Oct-20
Undisclosed
Target:
Cosmetic applications endolysin
Acquiror:
L’Oréal
Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100
15-Sep-20
$NA
Target:
Surgery Partners’ Anesthesia Services
Acquiror:
NorthStar Anesthesia
Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia
12-Aug-20
$225 million
Target:
340B Link
Acquiror:
Omnicell
Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
10-Jun-20
$134 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
03-Jun-20
$NA
Target:
Cerner RevWorks
Acquiror:
R1 RCM
Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
18-Mar-20
$NA
Target:
Centrifuge and processing equipment business of Koki Holdings Co., Ltd.
Acquiror:
Eppendorf AG
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
03-Mar-20
$NA
Target:
Formation of an incorporated joint venture
Acquiror:
BBI Group
Advised Flinders Mines, an ASX-listed mining exploration and development company, on the formation of an incorporated joint venture with BBI Group, providing a structure for the potential integrated financing and development of Flinders’ Pilbara Iron Ore Project and BBI Group’s Balla Balla rail and port infrastructure project
02-Mar-20
$NA
Target:
Global rights (excluding North America) to ThermaCare (United Kingdom)
Acquiror:
Angelini Pharma
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
20-Feb-20
$NA
Target:
Asia and US rights to Physiogel
Acquiror:
LG Household & Health Care
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
15-Jan-20
$NA
Target:
OurHealth
Acquiror:
General Atlantic
Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health
14-Jan-20
$537 million
Target:
Hycroft Mining Corporation
Acquiror:
Mudrick Capital Acquisition Corporation
Advised Hycroft Mining Corporation, a US-based, gold and silver producer operating the Hycroft mine located in Northern Nevada, on the sale of substantially all of its assets to Mudrick Capital Acquisition Corporation